Broadcom on Thursday said its AI revenue will double in the current quarter, but shares slumped as investors focused on ...

From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a ...

Apellis Pharmaceuticals, Inc. faces a Sell rating amid revenue stagnation, Syfovre challenges, and uncertain long-term profit ...

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

If you have ever wondered whether Regeneron Pharmaceuticals is a smart buy at around $718 a share, you are not alone; investors are trying to figure out if the current price really reflects its long ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Eli Lilly and Company. Read 's Market Analysis on Investing.com ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $82.5 billion by ...